Medicus Pharma Expands Phase 2 BCC Clinical Study to the UK

Medicus Pharma Ltd ( (MDCX) ) just unveiled an announcement.

Medicus Pharma Ltd. has received full regulatory and ethical approvals in the United Kingdom to expand its Phase 2 clinical study (SKNJCT-003) for a non-invasive treatment of basal cell carcinoma (BCC) using Doxorubicin Microneedle Array (D-MNA). This expansion allows the company to enhance global patient recruitment and clinical datasets, supporting its pivotal study program. The study, already underway in the United States, will now include additional sites in the UK, further establishing Medicus’s global footprint in the market. The company’s efforts are bolstered by positive interim analysis results and FDA feedback, indicating potential for significant advancements in non-invasive BCC treatment.

The most recent analyst rating on (MDCX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.

Spark’s Take on MDCX Stock

According to Spark, TipRanks’ AI Analyst, MDCX is a Underperform.

Medicus Pharma Ltd’s financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability.

To see Spark’s full report on MDCX stock, click here.

More about Medicus Pharma Ltd

Medicus Pharma Ltd. is a biotech and life sciences company focused on advancing clinical development programs for novel and potentially disruptive therapeutic assets. The company is involved in developing non-invasive treatments for basal cell carcinoma (BCC) of the skin, with a market opportunity exceeding $2 billion.

Average Trading Volume: 370,440

Technical Sentiment Signal: Sell

Current Market Cap: $48.92M

See more data about MDCX stock on TipRanks’ Stock Analysis page.